Results (
Thai) 2:
[Copy]Copied!
We enrolled pregnant women between 14 and
32 weeks of gestation at high risk of pre-eclampsia
who were receiving prenatal care at the Instituto
Nacional de Perinatologia Isidro Espinosa de los
Reyes in Mexico City between January 2001 and
December 2005. We included patients at increased
risk of pre-eclampsia, which we defined as either a per-
sonal history of pre-eclampsia or pre-eclampsia in a
first degree relative. Eligible participants agreed to
have their prenatal care and delivery at the institution
and provide informed consent. We excluded patients
with multiple gestation, known major fetal anomalies
(as defined by ultrasound studies by the fetal medicine
department), diabetes mellitus or gestational diabetes,
pre-existing hypertension, pre-existing renal disease,
collagen vascular disease, cancer or strong family his-
tory of cancer in first degree relatives, and pre-existing
maternal disease needing drug treatment. We
excluded women with type 2 diabetes, cancer, or a
strong family history of cancer because the angiogenic
actions of vascular endothelial growth factor are
thought to be mediated, in part, by nitric oxide.
32
All
women were screened for gestational diabetes at week
14 and again at week 24 of gestation, according to the
institutional protocol. We decided in advance that if a
woman was diagnosed as having gestational diabetes
after randomisation she would discontinue taking bars
because of the aforementioned safety concerns. How-
ever,weincludedsuchwomeninthedataanalysis.We
excluded patients with autoimmune disease because
peroxynitrites have been implicated in the pathogen-
esis of tissue damage in autoimmune disease.
Being translated, please wait..
